ArticlePloS one2018

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.

Jesús Troya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.